CCND3 Expression serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain CCND3 Expression as an inclusion criterion, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (1 open).
Trials with CCND3 Expression in the inclusion eligibility criteria most commonly target mantle cell lymphoma and squamous cell lung carcinoma .
Ibrutinib, palbociclib, and rituximab are the most frequent therapies in trials with CCND3 Expression as an inclusion criteria .
Significance of CCND3 Expression in Diseases
Mantle Cell Lymphoma +
CCND3 Expression is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 Expression and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) .
Squamous Cell Lung Carcinoma +
CCND3 Expression is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 Expression and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.